title: Cerebral monoamine oxidase A inhibition in tobacco smokers confirmed with PET and [11C]befloxatone.
abstract: The inhibition of cerebral monoamine oxidases (MAOs) by cigarette smoke components could participate to the tobacco addiction. However, the actual extent of this inhibition in vivo in smokers is still poorly known. We investigated cerebral MAO-A availability in 7 tobacco-dependent subjects and 6 healthy nonsmokers, using positron emission tomography (PET) and the MAO-A selective radioligand [C]befloxatone. In comparison to nonsmokers, smokers showed a significant overall reduction of [C]befloxatone binding potential (BP) in cortical areas (average reduction, -60%) and a similar trend in caudate and thalamus (-40%). Our findings confirm a widespread inhibition of cerebral MAO-A in smokers. This mechanism may contribute to tobacco addiction and for a possible mood-modulating effect of tobacco.
authors.affiliation: INSERM U797, Research Unit Neuroimaging and Psychiatry, Orsay, France. claire.leroy@cea.fr
authors.forename: Claire
authors.initials: C
authors.lastname: Leroy
authors.forename: Véronique
authors.initials: V
authors.lastname: Bragulat
authors.forename: Ivan
authors.initials: I
authors.lastname: Berlin
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Grégoire
authors.forename: Michel
authors.initials: M
authors.lastname: Bottlaender
authors.forename: Dimitri
authors.initials: D
authors.lastname: Roumenov
authors.forename: Frédéric
authors.initials: F
authors.lastname: Dollé
authors.forename: Sandrine
authors.initials: S
authors.lastname: Bourgeois
authors.forename: Jani
authors.initials: J
authors.lastname: Penttilä
authors.forename: Eric
authors.initials: E
authors.lastname: Artiges
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Martinot
authors.forename: Christian
authors.initials: C
authors.lastname: Trichard
mesh_terms: D000328:Adult; D002250:Carbon Radioisotopes; D002540:Cerebral Cortex / Q000000981:diagnostic imaging* / Q000201:enzymology*; D006801:Humans; D008297:Male; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D009538:Nicotine / Q000008:administration & dosage / Q000494:pharmacology; D018722:Nicotinic Agonists / Q000008:administration & dosage / Q000494:pharmacology; D010080:Oxazoles / Q000493:pharmacokinetics*; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D012907:Smoking / Q000503:physiopathology; D014018:Tissue Distribution
chemical_list: D002250:Carbon Radioisotopes; D008996:Monoamine Oxidase Inhibitors; D018722:Nicotinic Agonists; D010080:Oxazoles; D019275:Radiopharmaceuticals; C090014:befloxatone; D009538:Nicotine; D008995:Monoamine Oxidase